Antonio Passaro
European Institute of Oncology · 225 works · 10,149 citations · h-index 44
Top works
- COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
- Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
- Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists’ perspective
- Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
- Overcoming therapy resistance in EGFR-mutant lung cancer
- Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
- LBA15 Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial
- Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
- Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies
- Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies
- Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations
- Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC
- Immunotherapy in Non–Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence
- ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer
- Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC
- ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
- Testing for COVID-19 in lung cancer patients
- Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study